Potential for micro-RNA based cancer treatments

Understanding the mechanisms of breast cancer resistance

Bevacizumab benefits beyond progression in TML study subgroups

Pharmacodynamic endpoints need to be included in GI trials

Exploring new targets in GI cancer

Unravelling mechanisms of resistance to targeted drugs

CORRECT study data prompts US FDA priority review

Translational and tailored, but can we afford it?

Translational and tailored, but can we afford it?

Cost efficiency of targeted therapy

Society and money - the cancer conundrum

Translating cancer research to personalised treatment: Can it work?